Spectral AI Secures Major BARDA Funding for DeepView

Spectral AI ( (MDAI) ) has shared an update.

On March 18, 2026, Spectral AI announced it had been awarded $31.7 million in additional non-dilutive funding from the U.S. Biomedical Advanced Research and Development Authority to accelerate new feature development for its DeepView System, an AI-based burn wound imaging technology, with the company committing a further $9.7 million of its own capital. The funding, which comes on top of $54.9 million previously committed under a BARDA contract valued at up to $150 million, supports ongoing work toward U.S. Food and Drug Administration clearance and broader deployment of DeepView as a critical tool for emergency departments, trauma and burn centers, and federal preparedness for mass casualty burn incidents, reinforcing Spectral AI’s position in advanced burn diagnostics amid significant gaps in U.S. burn care capacity.

By backing enhancements such as total body surface area mapping and analysis, the expanded BARDA support underscores the strategic role of DeepView in helping clinicians rapidly triage and treat burn patients, particularly when demand overwhelms the limited number of burn centers and specialists nationwide. For Spectral AI, the award strengthens its long-standing government partnership, provides substantial immediate capital without shareholder dilution, and advances the company toward commercial readiness for its technology in both routine clinical settings and national emergency response frameworks.

The most recent analyst rating on (MDAI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Spectral AI stock, see the MDAI Stock Forecast page.

Spark’s Take on MDAI Stock

According to Spark, TipRanks’ AI Analyst, MDAI is a Neutral.

The score is held down primarily by weak financial performance (revenue contraction, large losses, negative equity, and ongoing cash burn). Technicals provide a partial offset with improving near-term momentum, while valuation remains constrained by unprofitability and no dividend support. The latest earnings call was mixed, with solid liquidity and FDA progress outweighed by reduced guidance and worsening near-term profitability.

To see Spark’s full report on MDAI stock, click here.

More about Spectral AI

Spectral AI, Inc. is a Dallas-based predictive artificial intelligence company specializing in medical diagnostics to support faster and more accurate treatment decisions in wound care, with an initial focus on burn patients. Its flagship product, the DeepView System, is being developed as an AI-driven imaging and predictive diagnostic device to give clinicians objective, immediate assessments of burn wounds’ healing potential, aiming to improve outcomes and reduce healthcare costs.

Average Trading Volume: 510,475

Technical Sentiment Signal: Sell

Current Market Cap: $43.58M

Find detailed analytics on MDAI stock on TipRanks’ Stock Analysis page.